Your session is about to expire
Aricept vs Exelon
Introduction
For patients diagnosed with Alzheimer's disease or other forms of dementia, certain medications can help manage symptoms by affecting the levels of signaling chemicals in the brain, called neurotransmitters. Aricept and Exelon are two such drugs that are commonly prescribed for these conditions. They each influence different neurotransmitter pathways but both aim to maintain cognitive function and slow symptom progression. Aricept is a cholinesterase inhibitor, which works by boosting levels of acetylcholine—a neurotransmitter involved in memory and learning—by preventing its breakdown. On the other hand, Exelon also falls under the category of cholinesterase inhibitors but it additionally acts on glutamatergic systems by binding to NMDA receptors; primarily assisting not only with acetylcholine levels but also regulating glutamate activity—a crucial component for learning and memory.
What is Aricept?
Donepezil (the generic name for Aricept) is an acetylcholinesterase inhibitor which marked a significant advancement following the initial class of Alzheimer's disease drugs. Donepezil was first given approval by the FDA in 1996. Aricept works by increasing levels of acetylcholine, a neurotransmitter involved in memory and learning, by preventing its breakdown, effectively enhancing its presence in the brain for longer periods than usual. It is prescribed largely to treat symptoms associated with Alzheimer's disease.
Aricept has a selective influence on acetylcholine which results in it having fewer side effects than other dementia medications that have stronger influences on additional neurotransmitters. On the other hand, Rivastigmine (Exelon), also an acetylcholinesterase inhibitor like Donepezil, has dual-action inhibitory effects on both butyryl-cholinesterase and acetyl-cholinesterase which may lead to more pronounced side effects such as nausea and vomiting.
What conditions is Aricept approved to treat?
Aricept is approved for the treatment of various stages of Alzheimer's disease:
- Mild to moderate Alzheimer's Disease
- Moderate to severe Alzheimer's Disease
Exelon, on the other hand, has been approved for:
- Mild to moderate dementia related with Parkinson’s disease.
- Mild to moderate dementia associated with Alzheimer's disease.
How does Aricept help with these illnesses?
Aricept helps manage symptoms of Alzheimer's disease by increasing the amount of acetylcholine available in the brain. It accomplishes this by inhibiting an enzyme called acetylcholinesterase, which breaks down acetylcholine, a vital neurotransmitter involved in learning and memory processes. By doing so, levels can be maintained higher for longer periods of time. Scientists believe that individuals with Alzheimer's have relatively lower levels of acetylcholine in certain areas of their brain. Therefore, by boosting its presence through Aricept, adverse effects linked to memory loss and cognitive impairment associated with Alzheimer’s disease can be mitigated, helping patients manage their condition more effectively.
What is Exelon?
Exelon, whose generic name is rivastigmine, is an acetylcholinesterase inhibitor that works by increasing the levels of a certain natural substance (acetylcholine) in the brain. Exelon acts to prevent the breakdown of this neurotransmitter at cholinergic synapses. This drug was first approved by the FDA in 2000 and it is used primarily for treatment-associated symptoms with Alzheimer's disease and Parkinson’s Disease Dementia.
As rivastigmine does not belong to NMDA receptor antagonists like Memantine, it does not block glutamatergic neurotransmission. Consequently, its side-effect profile differs from that of drugs such as Aricept (donepezil), another acetylcholinesterase inhibitor. It particularly tends not to cause common side effects associated with many dementia medications such as sedation or severe gastrointestinal problems. The increased acetylcholine provided can be beneficial for patients suffering from cognitive impairment related to these degenerative conditions who do not respond optimally to other treatments.
What conditions is Exelon approved to treat?
Exelon is approved for the treatment of:
- Mild to moderate Alzheimer's disease
- Mild to moderate dementia associated with Parkinson's disease
This drug, available in both patch and oral form, can help manage symptoms of these conditions such as confusion and memory loss. It works by preventing the breakdown of acetylcholine, a chemical that is significant in processes like memory formation and learning.
How does Exelon help with these illnesses?
Acetylcholine is a vital neurotransmitter involved in memory, concentration, and overall brain function. As such, it plays an integral role in conditions like Alzheimer's disease where these functions are compromised. Exelon works by inhibiting the breakdown of acetylcholine through blocking the enzyme acetylcholinesterase which degrades this neurotransmitter in our bodies. By doing so, Exelon increases the levels of acetylcholine available to neurons enhancing communication and potentially improving cognitive function for patients with dementia or similar disorders. Although Aricept also operates on a similar principle, Exelon additionally acts on butyrylcholinesterase - another enzyme that breaks down acetylcholine - offering a broader spectrum approach towards maintaining optimal acetylcholine levels for cognitive health.
How effective are both Aricept and Exelon?
Both donepezil (Aricept) and rivastigmine (Exelon) have well-established histories in helping patients with Alzheimer's disease, and they were approved by the FDA only a few years apart. They both work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and learning, that is lower than normal in people with Alzheimer's.
A 2005 double-blind clinical trial directly studied donepezil against rivastigmine for their effectiveness at alleviating symptoms of mild to moderate Alzheimer’s disease; results indicated similar efficacy between the two drugs as well as comparable safety profiles. In this study, there was no significant difference on any measures of cognition or daily living activities between patients receiving Aricept compared to those receiving Exelon.
An extensive review published in 2018 demonstrated that both medications can stabilize or slow down cognitive decline over six months to one year. Both drugs are generally well tolerated, although gastrointestinal side effects like nausea and vomiting may be somewhat more common with Exelon.
Despite these similarities, there are differences worth discussing when choosing treatment options: Donepezil is available as once-daily tablet while rivastigmine can be taken twice daily as a capsule or applied once daily through skin patch which might offer convenience for some users who struggle swallowing pills. Furthermore, donepezil has shown benefit across all stages of Alzheimer’s - mild to severe- whereas rivastigmine has been mainly effective for early stage dementia.
Nonetheless due to its unique pharmacology profile mimicking brain natural neurochemical balance and ability deliver steady drug concentration minimizing peak-related dose dependent side effects via its innovative transdermal patch form , Rivastigmine might be an optimal treatment choice for patients who did not respond well to other cholinesterase inhibitors treatments or prone certain side effects such bradycardia commonly seen among elderly population taking these kind medications .
At what dose is Aricept typically prescribed?
Aricept is typically started at a dose of 5 mg/day and can be increased to a maintenance dosage of 10 mg/day after four to six weeks if needed. For severe Alzheimer's disease, the dosage may eventually be increased up to 23 mg/day. On the other hand, Exelon is generally initiated at a low dose of 1.5 mg twice daily and could be gradually increased every two weeks by increments of 1.5mg per day based on tolerance towards the medication. The maximum recommended daily dosage for Exelon should not exceed 6-12mg split into two doses in any case.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Exelon typically prescribed?
Treatment with Exelon typically begins at a starting dose of 1.5 mg taken twice daily, totaling to 3mg/day. The dosage can then be increased after a minimum of two weeks to 3 mg twice daily, equating to an overall dose of 6mg/day. If well tolerated and if there is no significant therapeutic response observed, the dose could further be increased every two weeks up to the maximum recommended dose of 12mg/day divided into two doses (i.e., 6 mg twice daily). Remember that this upward adjustment should only occur under medical supervision and if there has not been enough response from previous dosages after few weeks.
What are the most common side effects for Aricept?
Common side effects of Aricept and Exelon may include but are not limited to:
- Nausea, vomiting
- Diarrhea
- Loss of appetite (anorexia)
- Muscle weakness (asthenia)
- Dizziness
- Insomnia or somnolence (sleepiness/drowsiness)
- Unintentional weight loss.
In addition, some patients may experience more serious side effects such as slow heartbeat, fainting, trouble urinating, seizures. Always consult with your healthcare provider for a complete list of possible side effects and interactions with other medications you're taking.
Are there any potential serious side effects for Aricept?
While taking Aricept, a medication commonly used to treat symptoms of Alzheimer's disease, it's important to monitor for any potential side effects. Rare but serious side effects can include:
- Signs and symptoms of low heart rate such as fainting, dizziness, or feeling like you might pass out
- Symptoms suggestive of stomach ulcers: severe abdominal pain, blood in stools or vomit that resembles coffee grounds
- Difficult or painful urination
- Seizures (convulsions)
- New or worsening breathing problems such as shortness of breath
- Allergic reactions: hives; difficulty breathing; swelling around the face/lips/tongue/throat
Exelon also treats Alzheimer's disease and may cause similar side effects along with additional ones such as:
-Agitation or aggression -Tremors (uncontrolled shaking) -Unusual weight loss
If any of these conditions present while on either drug regimen, immediately seek medical attention.
What are the most common side effects for Exelon?
Exelon, like many medications, can cause a variety of side effects. These can include:
- Nausea and vomiting
- Decreased appetite, leading to weight loss
- Diarrhea or abdominal pain
- Headache or dizziness
- Fatigue and generalized weakness
- Increased sweating
- Sleep problems including insomnia -Tremors in some patients
These are common side effects that may occur when starting the medication as your body adjusts. Less commonly but more seriously, Exelon could potentially cause a slow heartbeat, fainting spells, black stools or stomach bleeding. If you notice these symptoms seek immediate medical attention.
Are there any potential serious side effects for Exelon?
Exelon, while highly effective for treating symptoms of Alzheimer's and Parkinson's disease-related dementia, can occasionally cause adverse reactions. If you or a loved one taking Exelon begins to experience any of the following symptoms, seek medical attention immediately:
- Signs of an allergic reaction: hives; difficulty breathing; swelling in your face, lips, tongue or throat.
- Severe nausea, vomiting, diarrhea
- Bloody or tarry stools
- New or worsening chest pain
- Unexplained weight loss
- Dehydration signs like being unusually thirsty or urinating less than usual
- Light-headedness feeling that could lead to fainting
- Tremors (uncontrolled shaking)
Remember that this is not a complete list and other side effects may arise. Call your doctor right away if you have serious side effects while taking Exelon.
Contraindications for Aricept and Exelon?
Both Aricept and Exelon, like most other drugs for Alzheimer's disease, may worsen symptoms in some individuals. If you or someone close to you notices an increase in agitation, confusion, hostility or hallucinations after administering these medications, please seek immediate medical attention.
Neither Aricept nor Exelon should be used if you are taking certain types of antifungal medication (ketoconazole), antidepressants (fluoxetine) and particular heart rhythm medicines (quinidine). Always inform your physician about all the medications that you are currently taking; these aforementioned medications may interact negatively with Aricept and Exelon causing harmful side effects. It is recommended to wait for a period of about 4 weeks after stopping such treatments before starting either Aricept or Exelon.
How much do Aricept and Exelon cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Aricept (10 mg) averages around $800, which works out to approximately $26.67/day.
- The price for 60 patches of Exelon (9.5 mg/24h) is about $680, working out to roughly $11.33/day.
Thus, if you are on a standard dosage for both medications, then brand-name Exelon is less expensive on a per-day treatment basis compared to Aricept. Please note that cost should not be your primary consideration in determining which of these Alzheimer's disease drugs is right for you or your loved one.
For the generic versions donepezil (Aricept) and rivastigmine (Exelon), costs are significantly lower:
- Donepezil (10 mg tablets) is available in packs ranging from 30 to 90 capsules with approximate costs starting at around $0.27 per day.
- Rivastigmine patches vary greatly in cost depending on strength and quantity but can start as low as about $1 per day.
Taking into account only the medication prices without insurance coverage or discount plans, generic donepezil appears cheaper than generic rivastigmine based on typical dosages used in treating Alzheimer's disease symptoms.
Popularity of Aricept and Exelon
Donepezil, available under the brand name Aricept, was estimated to have been prescribed to about 1.8 million people in the US in 2020. Donepezil is one of the commonly used medications for managing symptoms of Alzheimer's disease and accounted for approximately 50% of prescriptions for this purpose. Over the last decade, its use has remained relatively steady.
Rivastigmine, with brand versions such as Exelon, was prescribed to an estimated 500 thousand people in America during that same year. Rivastigmine makes up around 16% of prescriptions aimed at managing Alzheimer's disease symptoms. Despite these figures indicating a lower overall usage compared to donepezil, it's worth noting that rivastigmine is also approved by FDA for treatment of dementia associated with Parkinson’s disease which diversifies its application range.
Conclusion
Both Aricept (donepezil) and Exelon (rivastigmine) have long-standing records of usage in patients with Alzheimer's disease, and are backed by numerous clinical studies indicating that they can help slow down the progression of cognitive decline associated with this condition. Both drugs work by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and learning.
Aricept is often prescribed as first-line therapy for all stages of Alzheimer’s disease due to its once-daily dosing and availability in both tablet and orally disintegrating tablet forms. On the other hand, Exelon is typically used for mild to moderate stages of Alzheimer's disease and Parkinson’s-related dementia. It comes as a capsule or patch which can be beneficial if swallowing pills becomes difficult.
Both medications are available in generic form which represents significant cost savings especially for patients who must pay out-of-pocket. The side effect profile is similar between the two drugs; common side effects include nausea, vomiting, loss of appetite and diarrhea but these usually lessen over time as your body adjusts to treatment.
It is crucial for caregivers or family members to closely monitor changes in behavior or worsening symptoms when starting on either medication since people with dementia may not be able to communicate effectively about their health status.